PDF

Int J Biol Sci 2022; 18(6):2292-2303. doi:10.7150/ijbs.69411 This issue Cite

Review

The role of ubiquitination and deubiquitination in tumor invasion and metastasis

Shuangze Han¹, Ruike Wang¹, Yangnan Zhang¹, Xiaoying Li¹, Yu Gan¹, Feng Gao³ , Pengfei Rong^1,2 , Wei Wang^1,2 , Wei Li^1,2

1. Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China
2. Cell Transplantation and Gene Therapy Institute, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China
3. Department of Ultrasonography, The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China

✉ Corresponding authors: Feng Gao, E-mail: gf0731edu.cn. Pengfei Rong, E-mail: rongpengfei66com. Wei Wang, E-mail: cjr.wangwei163.com. Wei Li, E-mail: weililxedu.cn. Tel: +86-0731-88618643

Abstract

Ubiquitination is vital for multiple cellular processes via dynamic modulation of proteins related to cell growth, proliferation, and survival. Of the ubiquitination system components, E3 ubiquitin ligases and deubiquitinases have the most prominent roles in modulating tumor metastasis. This review will briefly summarize the observations and underlying mechanisms of multiple E3 ubiquitin ligases and deubiquitinases to regulate tumor metastasis. Further, we will discuss the relationship and importance between ubiquitination components and tumor progression.

Keywords: ubiquitination, E3 ubiquitin ligase, deubiquitinase, metastasis

A brief overview of the ubiquitination process

Protein ubiquitination is a dynamic, multifaceted post-translational modification involved in multiple cellular processes. Ubiquitin (Ub), a 76-amino acid protein, features seven lysine residues (K6, K11, K27, K29, K33, K48, and K63), which can each be ubiquitinated to form distinctive forms of polyubiquitin chains. Different polyubiquitin chains mediate distinct signaling pathways to determine the fate of substrate proteins [1]. For example, K48/K11-linked chains are responsible for targeting substrate proteins for proteasomal degradation, while other chains perform non-degradative roles in controlling protein interactions, cellular localization, and signaling transduction (Fig. 1).

Ubiquitination is catalyzed by a three-enzyme cascade composed of the E1 Ub-activating enzyme, the E2 Ub-conjugating enzyme, and the E3 Ub ligase. E1 recruits and activates Ub by utilizing the energy of ATP. Activated Ub is transferred to E2, which can transfer Ub to the target substrate. E3 Ub ligase selectively recognizes a substrate protein by forming an iso-peptide bond between the COOH-terminal glycine of Ub and a lysine residue of the substrate. In addition, E3 Ub ligase recruits the E2-Ub complex and catalyzes the transfer of Ub to the substrate from E2 [2]. Different subtypes of E3s (the RING type E3s, the HECT type E3s, and the RBR type E3s) are the most critical component of the ubiquitination cascade for the substrate recognition capacity [2]. Meanwhile, ubiquitination is a dynamic and reversible process. Deubiquitinases (DUBs) can act as an “eraser” that reverses Ub signals. Most DUBs remove Ub moieties from proteins to prevent substrate proteins from degradation. However, some proteasome-related DUBs, including USP14, UCHL5, PSMD14, and PSMD7, are localized in 19S particles of the proteasome [3]. The roles of these DUBs are to deubiquitinate the substrates and facilitate their degradation in 20S particles of the proteasome. Alternatively, DUBs can alter signals by non-degradation ubiquitination [4] (Fig. 1).

The Ub cascade and DUBs synergistically regulate protein turnover and function in numerous signaling pathways to maintain cellular invasion and metastasis.

A novel insight into tumor metastasis

Tumor metastasis remains the primary cause of cancer-associated mortality. Metastasis involves tumor cell motility, intravasation into the adjacent tissues, circulation, and extravasation to distant organs. Simultaneously, the process is caused by genome instability where cancer cells can reprogram tumor metabolism, resist cell death, avoid immune destruction, and constitute the tumor microenvironment [5, 6]. The epithelial-mesenchymal transition (EMT) is an equally crucial determinant during the metastatic cascade [7].

Ubiquitination and deubiquitination broadly participate in various processes involved in protein modification and regulation. Aberrant dysregulation induces tumorigenesis. This review is primarily focused on recent novel observations and underlying mechanisms concerning E3 ligases and DUBs in order to contribute to further elucidating the role of ubiquitination and deubiquitination in tumor invasion and metastasis.

E3 Ub ligases inhibiting metastasis

F-box and WD-repeat domain-containing 2 (FBXW2)

FBXW2 is a substrate recognition receptor in the SKP1-Cullin1-F-box protein (SCF) E3 Ub ligase complex. FBXW2 suppresses proliferation and invasion of lung cancer cells by targeting S phase kinase-associated protein 2 (SKP2) and β-catenin (Fig. 2). FBXW2 is downregulated and negatively correlated with β-catenin in lymph-node metastasis [8, 9]. Meanwhile, FBXW2 is a novel substrate of β-transducin repeat-containing protein 1 (β-TrCP1). Following growth factor stimulation, β-TrCP1 targets FBXW2 for ubiquitination degradation. The accumulation of SKP2 subsequently leads to the degradation of tumor suppressors and apoptosis-inducing substrates, such as p21, p27, p130, and FOXO1, to promote tumor cell proliferation, growth, and survival [8]. The β-TrCP-FBXW2-SKP2 signaling cascade forms the oncogene (β-TrCP1)-tumor suppressor gene (FBXW2)-oncogene (SKP2) axis that regulates the growth and survival of lung cancer cells via targeting each other for degradation, which is a process of crucial crosstalk among F-box proteins. In hepatocellular carcinoma (HCC), FBXW2 targets transforming growth factor-β-activated kinase 1 (TAK1) for K48-linked polyubiquitination and degradation to inhibit cancer progression [10] (Fig. 2). Clinically, FBXW2 levels could be a significant indicator of the prognosis and survival of patients with cancer.

F-box and WD repeat domain-containing 7 (FBW7)

FBW7 is a substrate recognition receptor of the SCFFBW7 E3 Ub ligase complex. It functions as a tumor suppressor and mediates ubiquitination-induced degradation of various oncogenic proteins, including c-MYC, NOTCH, c-JUN, and cyclin E [11]. In gastric cancer, transcription activator Brg1 (Brg1) binds to the promoter of Snail, which subsequently promotes EMT and metastasis. Meanwhile, Brg1 is a Ub substrate of the SCFFBW7 E3 ligase complex. Casein kinase 1 (CK1)δ-mediated phosphorylation at Ser31/Ser35 sites of Brg1 strengthens FBW7-binding capacity, thus accelerating the ubiquitination of Brg1[12] (Fig. 2). Methylation induces epigenetic silencing of the FBW7 gene. Decitabine (DAC) epigenetically activates FBW7 expression via its demethylation. DAC-activated FBW7 promotes myeloid leukemia cell differentiation protein Mcl-1 ubiquitination and degradation to suppress lung cancer growth [13]. YTH domain-containing family protein 2 (YTHDF2) is the N6-methyladenosine (m6A) reader protein and promotes the decay of the m6A-modified mRNAs. FBW7 can degrade YTHDF2 by ubiquitination and suppress the propagation of ovarian cancer [14] (Fig. 2).

Putative E3 Ub-protein ligase UBR7 (UBR7)

UBR7 belongs to the Ub-protein ligase E3 component N-recognin (UBR) family and has a unique plant homeodomain (PHD) finger [15]. PHD fingers are central “readers” of histone post-translational modifications [16]. UBR7-PHD finger monoubiquitinates histone H2B in triple-negative breast tumors at lysine 120 (H2BK120Ub). H2BK120Ub enhances cadherin-4 (CDH4) transcription activity and expression level [15]. CDH4 overexpression notably suppresses EMT and reduces cellular proliferation, migration, and invasion [15] (Fig. 2). Meanwhile, CDH4 can regulate the Wnt/β-catenin signaling pathway. It alters the nuclear localization of β-catenin to the cytoplasm, which downregulates β-catenin target genes, including AXIN2, G1/S-specific cyclin-D1, C-MYC, COX2, and MMP7, to suppress tumor metastasis [17, 18].

Parkin

Notably, as an E3 Ub ligase, Parkin can degrade substrate proteins associated with Parkinson's Disease (PD) [19]. Meanwhile, Parkin acts as a tumor suppressor, and its expression is downregulated in various tumors [20]. Parkin is an E3 Ub ligase for hypoxia-inducible factor 1α (HIF-1α) and can ubiquitinate HIF-1α at lysine 477 (K477), inhibit HIF-1α transcriptional activity, and induce its degradation to suppress breast cancer cells invasion and metastasis [21, 22]. Parkin regulates HIF-1α in a Von Hippel-Lindau-independent manner, unveiling an additional layer of regulation for HIF-1α in cells. Phosphoglycerate dehydrogenase (PHGDH) is the first rate-limiting enzyme of serine synthesis. PHGDH overexpression activates serine synthesis to promote cancer progression. Parkin expression is inversely correlated with PHGDH expression in breast and lung cancer. Parkin interacts with PHGDH and ubiquitinates PHGDH at lysine 330, leading to PHGDH degradation to suppress serine synthesis [23]. In intrahepatic cholangiocarcinoma (ICC), Parkin targets pyruvate kinase PKM2 for ubiquitination degradation to suppress migration and proliferation [24] (Fig. 2).

 Figure 1 

A brief overview of the ubiquitination pathway. Ubiquitination is catalyzed by a three-enzyme cascade composed of the E1 Ub-activating enzyme, the E2 Ub-conjugating enzyme, and the E3 Ub ligase. The E3 ligase selectively recognizes substrate proteins by forming an iso-peptide bond and recruits the Ub-E2 complex to catalyze the transfer of Ub to the substrate from E2. Elongation and distinct polyubiquitin chains are involved in protein degradation, signal transduction, and transcriptional activity. Deubiquitinases remove Ub moieties from substrate proteins with high specificity and reverse Ub signals to maintain cellular dynamic ubiquitination.

 Figure 2 

Different E3 Ub ligases regulate tumor metastasis. FBXW2 targets SKP2, β-catenin, and TAK1, FBW7 targets Brg1, Mcl-1, and YTHDF2, and Parkin targets HIF-1α, PHGDH, and PKM2 for ubiquitination degradation to suppress tumor proliferation and metastasis, respectively. UBR7 monoubiquitinates histone H2B to suppress EMT and nuclear β-catenin. UBE3C targets AHNAK and AXIN1 for ubiquitination-induced degradation. TRIM65 ubiquitinates ARHGAP35, FBXO22 ubiquitinates nuclear PTEN and p21 to enhance cancer cell migration, respectively. FBXO22 mediates Lys-63-linked LKB1 ubiquitination. FBXO22 upregulates HIF-1α and VEGFA to promote tumor proliferation and metastasis.

E3 Ub ligases promoting metastasis

Ub-protein ligase E3C (UBE3C)

UBE3C belongs to the HECT family of E3 Ub ligases. It functions as a tumor promoter and is aberrantly expressed in breast cancer [25], hepatocellular carcinoma [26], and renal cell carcinoma [27]. In non-small cell lung cancer (NSCLC) tissues, UBE3C maintains cancer stemness by ubiquitinating and promoting neuroblast differentiation-associated protein AHNAK (AHNAK) degradation [28]. AHNAK is a cofactor that assists P53 binding to stemness-related gene promoters. UBE3C-mediated degradation of AHNAK abrogates P53-AHNAK complex-mediated inhibition of gene expression, which enhances lung cancer cell stemness and NSCLC growth and metastasis [28, 29]. UBE3C targets AXIN1 for ubiquitination degradation to activate β-catenin signaling in gastric cancer [30] (Fig. 2).

Tripartite motif-containing protein 65 (TRIM65)

Tumor metastasis involves the reorganization of the cytoskeleton, whose activities are controlled by GTPases[31]. When bound to guanosine diphosphate (GDP), GTPases are inactivated, which is regulated by GTPase-activating protein (GAP)[32]. Rho A belongs to the Rho family of GTPases and regulates the cytoskeleton. Rho GTPase-activating protein 35 (ARHGAP35), a Rho GAP, regulates polarized cell migration and inhibits Rho GTPase. In colorectal cancer (CRC), E3 Ub ligase TRIM65 ubiquitinates and degrades ARHGAP35, which leads to subsequent elevated Rho GTPase activity and cytoskeleton remodeling [33] (Fig. 2). The TRIM65-ARHGAP35-Rho A axis enhances cancer cell migration by modulating the actin cytoskeleton.

F-box only protein 22 (FBXO22)

FBXO22, one of the F-box-only proteins, is the substrate-recognizing subunit of the SCF E3 Ub ligase complex [34]. FBXO22 ubiquitinates nuclear PTEN at lysine 221 (K221). Nuclear PTEN exerts potent tumor inhibition capacity. In CRC tissues, FBXO22 overexpression contributes to the downregulation of nuclear PTEN to promote tumorigenesis, which is reversed by the mutation of K221 [35]. FBXO22 is upregulated and negatively correlated with p21 in HCC. FBXO22 functions as an oncogene by mediating the ubiquitination and degradation of p21 to promote HCC pathogenesis and progression [36]. FBXO22 mediates Lys-63-linked liver kinase B1 (LKB1) polyubiquitination and inhibits LKB1-AMPK-mTOR signaling in lung adenocarcinoma [37]. FBXO22 promotes melanoma angiogenesis and migration of tumor cells via upregulating HIF-1α and vascular endothelial growth factor A (VEGFA) [38] (Fig. 2).

DUBs

DUBs can reverse ubiquitination by cleaving the isopeptide bond between the Ub and the substrate. Currently, over 100 DUBs have been identified and can be divided into six subclasses: i) Ub-specific proteases (USPs); ii) ovarian tumor proteases (OTUs); iii) Ub C-terminal hydrolases (UCHs); iv) Machado-Joseph disease proteases; v) JAB1/MPN/Mov34 metalloenzymes; and vi) monocyte chemotactic protein-induced protein[39]. DUBs act as tumor suppressors or oncogenes and play essential roles in regulating various types of tumors (Table 1). DUBs have emerged as promising therapeutic targets in cancer.

DUBs inhibiting metastasis

Ub carboxyl-terminal hydrolase BAP1 (BAP1)

BAP1 belongs to the UCH domain-containing proteins, and it can physically bind to and deubiquitinate PTEN to stabilize PTEN protein. Downregulated BAP1 leads to the decrease of PTEN protein levels and the activation of the Akt signaling pathway, therefore promoting malignant transformation and metastasis in prostate cancer. Clinically, low BAP1 expression is positively correlated with aggressive prostate tumor proliferation and lymphatic metastasis [40]. In ICC, BAP1 inhibits ERK1/2 and JNK/c-Jun pathways [41]. Moreover, BAP1 mediates the metabolic regulation of ferroptosis and tumor suppression. BAP1 reduces histone 2A ubiquitination (H2AUb) on the cystine/glutamate transporter (SLC7A11) promoter and represses SLC7A11 expression in a deubiquitination-dependent manner [42]. The loss of cystine transport mediated by SLC7A11 induces ferroptosis to inhibit tumor development and metastasis [43] (Fig. 3). In summary, as a major tumor suppressor, mutated BAP1 is associated with numerous human malignancies, which is defined as “BAP1 cancer syndrome” [44].

OTU domain-containing protein 1 (OTUD1)

In the TGF-β signaling pathway, SMAD7 recruits E3 ligase SMURF2 to TGF-β type I receptor (TβRI) [45]. However, E3 Ub-protein ligases RNF12 and Itchy homolog can degrade SMAD7 to antagonize its suppression [46, 47]. In breast cancer, OTUD1 can selectively eliminate the K48-linked Ub chain from SMAD7 to stabilize it (Fig. 3). Moreover, OTUD1 can cleave the K33-linked Ub chain on the lysine 220 site and unveil the PY motif of SMAD7 [48]. The exposed SMAD7 PY motif subsequently binds the WW domain of SMURF2 to degrade TβRI via ubiquitination [45, 49]. In summary, OTUD1 suppresses the TGF-β-induced metastasis by exerting dual effects on SMAD7.

Ub carboxyl-terminal hydrolase 43 (USP43)

The EGFR/PI3K/AKT pathway is aberrantly activated in various cancers [50]. PTEN can negatively regulate AKT kinase activity [51]. In addition, another molecular regulatory mechanism exists. Nuclear USP43 is physically associated with the nucleosome remodeling and deacetylase (NuRD) complex. The USP43-NuRD complex coordinately catalyzes H2BK120 deubiquitination to suppress downstream EGFR [52] (Fig. 3). Simultaneously, activated AKT can phosphorylate cytoplasmic USP43 on Ser29, phosphorylated USP43 is detained in the cytoplasm, reduced nuclear USP43 and accumulated EGFR potentiate the EGFR/PI3K/AKT pathway to promote breast cell proliferation and invasion [52]. USP43 is a hub of the USP43-NuRD complex, the reciprocally inhibitory loop between the USP43-NuRD complex and the EGFR/PI3K/AKT pathway synergistically modulates breast carcinogenesis. The ratio of nuclear/cytoplasmic USP43 is a worthy prognostic indicator [52].

DUBs promoting metastasis

USP7

USP7 can coordinate with histone-lysine N-methyltransferase EZH2 (EZH2)-catalyzed methylation to remove ubiquitination and enhance FOXA1 protein stability, promoting prostate cancer growth [53]. Moreover, USP7 can stabilize EZH2 via deubiquitination [54] (Fig. 3). USP7 is upregulated in M2 macrophages. USP7 inhibition can induce the polarization of tumor-associated macrophages from M2 into M1 by activating the P38 MAPK pathway and upregulating the expression of programmed cell death 1 ligand 1 (PD-L1) in the tumor microenvironment [55]. Therefore, USP7 blockade combined with anti-PD-1 immunotherapy exert an inhibitory effect on tumors in lung cancer.

SUMOylated-Ub thioesterase OTUB2 (OTUB2)

Transcriptional coactivator YAP1 (YAP) and tafazzin (TAZ) are generally downregulated by the canonical Hippo pathway [56]. However, YAP and TAZ are hyperactivated and induce tumor proliferation and metastasis, while the Hippo pathway is still active in multiple malignancies, including breast cancer [57, 58]. DUB OTUB2 mediates the activation of YAP and TAZ in a Hippo-independent manner (Fig. 3). Mechanistically, OTUB2 is poly-SUMOylated at lysine 233 (K233), SUMOylated-OTUB2 can subsequently bind YAP/TAZ through SUMO-interacting motif in YAP and TAZ [58]. OTUB2 deubiquitinates and activates YAP and TAZ, and accumulated YAP and TAZ translocate into the nucleus in which they interact with TEA domain family transcription factors and transcriptionally activate genes to potentiate cell proliferation and metastasis [59, 60]. Meanwhile, activated EGF-RAS signaling strengthens OTUB2 SUMOylation and elevates YAP/TAZ protein levels to promote cancer stemness and metastasis [58, 61]. In summary, the novel SUMOylated-OTUB2-mediated regulatory mechanism expands the complexity of YAP/TAZ beyond the Hippo pathway. OTUB2 may be a potential drug target to suppress cancer progression for patients harboring RAS mutations.

Dub3

Snail1 is a critical EMT-driving transcription factor and confers tumor metastatic and cancer stem cell-like properties [62]. The E3 ligases β-TrCP1 and F-box/LRR-repeat protein 14 (FBXL14) can degrade Snail1 via ubiquitination [63]. In breast cancer, Dub3 accounts for Snail1 stabilization, and inflammatory cytokine IL-6 can increase the expression of Dub3. Meanwhile, Dub3 also inhibits the activity of β-TrCP1 and FBXL14 to block Snail1 ubiquitination [64] (Fig. 3). Overall, Dub3 senses inflammatory stimulation and converts it into Snail1 stabilization.

 Figure 3 

Different DUBs regulate tumorigenesis. BAP1 can deubiquitinate PTEN and reduce H2AUb on the SLC7A11 promoter to inhibit tumor development and metastasis. OTUD1 can eliminate the K48-linked Ub chain from SMAD7. The USP43-NuRD complex catalyzes H2BK120 deubiquitination to suppress downstream EGFR. USP7 can stabilize EZH2 and FOXA1 via deubiquitination to promote tumor growth. USP7 upregulates PD-L1 expression in the tumor microenvironment. SUMOylated-OTUB2 deubiquitinates YAP/TAZ to potentiate tumor cell proliferation and metastasis in a Hippo-independent manner. Dub3 can stabilize Snail1 via deubiquitination and inhibiting β-TrCP1 and FBXL14-mediated ubiquitination degradation.

Conclusion

Although this brief review only scratches the surface of ubiquitination and deubiquitination in cancer, it highlights the significance of E3s and DUBs in a range of processes involved in tumor progression. Ubiquitination components are potential therapeutic targets for cancer treatment [65]. However, several issues remain obstacles for targeted therapy. DUBs share similar structural characteristics among family members, and ubiquitination involves substantial conformational changes. We still endeavor to deal with the challenges ahead, such as defining novel E3s, DUBs, and targeted substrates, investigating whether there exists unknown crosstalk among distinct E3s or DUBs, and decoding the unknown pathways linking ubiquitination with other cellular physiological mechanisms. Several valuable E3s or DUBs are promising clinical prognostic indexes and drug targets. Proteolysis Targeting Chimeras (PROTACs) exploit the intracellular Ub-proteasome system to degrade target proteins [66], selectively. In tumor xenografts, small-molecule PROTACs can significantly attenuate tumor progression [67].

This review provides a glimpse into the importance and extensiveness of ubiquitination component-mediated tumor invasion and metastasis, which represents a worthy research prospect.

Abbreviations

Ub: ubiquitin; DUBs: deubiquitinases; SKP2: S phase kinase-associated protein 2; FBXW2: F-box and WD-repeat domain-containing 2; TAK1: transforming growth factor-β-activated kinase 1; β-TrCP1: β-transducin repeat-containing protein 1; FBW7: F-box and WD repeat domain-containing 7; Brg1: transcription activator Brg1; Mcl-1: induced myeloid leukemia cell differentiation protein Mcl-1; YTHDF2: YTH domain-containing family protein 2; EMT: epithelial-mesenchymal transition; CK1: casein kinase 1; UBR7: putative E3 Ub-protein ligase UBR7; CDH4: cadherin-4; HIF-1α: hypoxia-inducible factor 1α; PHGDH: phosphoglycerate dehydrogenase; PKM: pyruvate kinase PKM; UBE3C: Ub-protein ligase E3C; AHNAK: neuroblast differentiation-associated protein AHNAK; TRIM65: tripartite motif-containing protein 65; ARHGAP35: Rho GTPase-activating protein 35; FBXO22: F-box only protein 22; LKB1: liver kinase B1; VEGFA: vascular endothelial growth factor A; BAP1: Ub carboxyl-terminal hydrolase BAP1; H2AUb: histone 2A ubiquitination; SLC7A11: cystine/glutamate transporter; SMURF2: E3 Ub-protein ligase SMURF2; TβRI: TGF-β type I receptor; OTUD1: OTU domain-containing protein 1; USP43: Ub carboxyl-terminal hydrolase 43; NuRD: nucleosome remodeling and deacetylase; H2BK120: histone H2B at lysine 120; USP: Ub-specific protease; EZH2: histone-lysine N-methyltransferase EZH2; PD-L1: programmed cell death 1 ligand 1; OTUB2: Ub thioesterase OTUB2; YAP: transcriptional coactivator YAP1; TAZ: tafazzin; FBXL14: F-box/LRR-repeat protein 14.

Acknowledgements

We apologize to colleagues whose work was not cited due to space limitations. This study was supported by China's National Natural Science Foundation (No.81972837).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26:399-422

2. Zheng N, Shabek N. Ubiquitin Ligases: Structure, Function, and Regulation. Annual review of biochemistry. 2017;86:129-57

3. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009;138:389-403

4. Clague MJ, Urbé S, Komander D. Breaking the chains: deubiquitylating enzyme specificity begets function. Nature reviews Molecular cell biology. 2019;20:338-52

5. Decoding cancer metastasis. Nat Cell Biol. 2018; 20: 859.

6. Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298-306

7. Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends in cell biology. 2019;29:212-26

8. Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y. et al. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun. 2017;8:14002

9. Yang F, Xu J, Li H, Tan M, Xiong X, Sun Y. FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation. Nat Commun. 2019;10:1382

10. Xia S, Ji L, Tao L, Pan Y, Lin Z, Wan Z. et al. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance. Cellular and molecular gastroenterology and hepatology. 2021;12:1121-43

11. Davis RJ, Welcker M, Clurman BE. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer cell. 2014;26:455-64

12. Huang LY, Zhao J, Chen H, Wan L, Inuzuka H, Guo J. et al. SCF(FBW7)-mediated degradation of Brg1 suppresses gastric cancer metastasis. Nat Commun. 2018;9:3569

13. Kim MJ, Chen G, Sica GL, Deng X. Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy. Cancer biology & therapy. 2021;22:55-65

14. Xu F, Li J, Ni M, Cheng J, Zhao H, Wang S. et al. FBW7 suppresses ovarian cancer development by targeting the N(6)-methyladenosine binding protein YTHDF2. Molecular cancer. 2021;20:45

15. Adhikary S, Chakravarti D, Terranova C, Sengupta I, Maitituoheti M, Dasgupta A. et al. Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. Nat Commun. 2019;10:1398

16. Jain K, Fraser CS, Marunde MR, Parker MM, Sagum C, Burg JM. et al. Characterization of the plant homeodomain (PHD) reader family for their histone tail interactions. Epigenetics & chromatin. 2020;13:3

17. Pohl SG, Brook N, Agostino M, Arfuso F, Kumar AP, Dharmarajan A. Wnt signaling in triple-negative breast cancer. Oncogenesis. 2017;6:e310

18. Li J, Zhou BP. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011;11:49

19. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015;85:257-73

20. Xu L, Lin DC, Yin D, Koeffler HP. An emerging role of PARK2 in cancer. Journal of molecular medicine (Berlin, Germany). 2014;92:31-42

21. Liu J, Zhang C, Zhao Y, Yue X, Wu H, Huang S. et al. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017;8:1823

22. LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol. 2016;18:356-65

23. Liu J, Zhang C, Wu H, Sun XX, Li Y, Huang S. et al. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. The Journal of clinical investigation. 2020;130:3253-69

24. Chen D, Wu H, Feng X, Chen Y, Lv Z, Kota VG. et al. DNA Methylation of Cannabinoid Receptor Interacting Protein 1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent Pyruvate Kinase M2 Ubiquitination. Hepatology (Baltimore, Md). 2021;73:1816-35

25. Xiong J, Wei B, Ye Q, Liu W. MiR-30a-5p/UBE3C axis regulates breast cancer cell proliferation and migration. Biochem Biophys Res Commun. 2019;516:1013-8

26. Jiang JH, Liu YF, Ke AW, Gu FM, Yu Y, Dai Z. et al. Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by exome sequencing. Hepatology (Baltimore, Md). 2014;59:2216-27

27. Wen JL, Wen XF, Li RB, Jin YC, Wang XL, Zhou L. et al. UBE3C promotes growth and metastasis of renal cell carcinoma via activating Wnt/β-catenin pathway. PloS one. 2015;10:e0115622

28. Gu J, Mao W, Ren W, Xu F, Zhu Q, Lu C. et al. Ubiquitin-protein ligase E3C maintains non-small-cell lung cancer stemness by targeting AHNAK-p53 complex. Cancer Lett. 2019;443:125-34

29. Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V. p53: the barrier to cancer stem cell formation. FEBS letters. 2014;588:2580-9

30. Zhang Y, Xu J, Fu H, Wei Z, Yang D, Yan R. UBE3C promotes proliferation and inhibits apoptosis by activating the β-catenin signaling via degradation of AXIN1 in gastric cancer. Carcinogenesis. 2021;42:285-93

31. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annual review of cell and developmental biology. 2005;21:247-69

32. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629-35

33. Chen D, Li Y, Zhang X, Wu H, Wang Q, Cai J. et al. Ubiquitin ligase TRIM65 promotes colorectal cancer metastasis by targeting ARHGAP35 for protein degradation. Oncogene. 2019;38:6429-44

34. Sun R, Xie HY, Qian JX, Huang YN, Yang F, Zhang FL. et al. FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression. Cancer Res. 2018;78:5274-86

35. Ge MK, Zhang N, Xia L, Zhang C, Dong SS, Li ZM. et al. FBXO22 degrades nuclear PTEN to promote tumorigenesis. Nat Commun. 2020;11:1720

36. Zhang L, Chen J, Ning D, Liu Q, Wang C, Zhang Z. et al. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21. J Exp Clin Cancer Res. 2019;38:101

37. Zhu XN, He P, Zhang L, Yang S, Zhang HL, Zhu D. et al. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth. Cell Death Dis. 2019;10:486

38. Zheng Y, Chen H, Zhao Y, Zhang X, Liu J, Pan Y. et al. Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway. Investigational new drugs. 2020;38:20-8

39. Sun J, Shi X, Mamun MAA, Gao Y. The role of deubiquitinating enzymes in gastric cancer. Oncology letters. 2020;19:30-44

40. Deng R, Guo Y, Li L, He J, Qiang Z, Zhang H. et al. BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN. Mol Oncol. 2021;15:279-98

41. Chen XX, Yin Y, Cheng JW, Huang A, Hu B, Zhang X. et al. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. Cell Death Dis. 2018;9:1036

42. Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20:1181-92

43. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060-72

44. Carbone M, Harbour JW, Brugarolas J, Bononi A, Pagano I, Dey A. et al. Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. Cancer discovery. 2020;10:1103-20

45. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH. et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell. 2000;6:1365-75

46. Park SH, Jung EH, Kim GY, Kim BC, Lim JH, Woo CH. Itch E3 ubiquitin ligase positively regulates TGF-β signaling to EMT via Smad7 ubiquitination. Molecules and cells. 2015;38:20-5

47. Zhang L, Huang H, Zhou F, Schimmel J, Pardo CG, Zhang T. et al. RNF12 controls embryonic stem cell fate and morphogenesis in zebrafish embryos by targeting Smad7 for degradation. Mol Cell. 2012;46:650-61

48. Zhang Z, Fan Y, Xie F, Zhou H, Jin K, Shao L. et al. Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nat Commun. 2017;8:2116

49. Chong PA, Lin H, Wrana JL, Forman-Kay JD. Coupling of tandem Smad ubiquitination regulatory factor (Smurf) WW domains modulates target specificity. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:18404-9

50. Horn D, Hess J, Freier K, Hoffmann J, Freudlsperger C. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. Expert opinion on therapeutic targets. 2015;19:795-805

51. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nature reviews Molecular cell biology. 2012;13:283-96

52. He L, Liu X, Yang J, Li W, Liu S, Liu X. et al. Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis. Cell Res. 2018;28:934-51

53. Park SH, Fong KW, Kim J, Wang F, Lu X, Lee Y. et al. Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Science advances. 2021 7

54. Zheng N, Chu M, Lin M, He Y, Wang Z. USP7 stabilizes EZH2 and enhances cancer malignant progression. American journal of cancer research. 2020;10:299-313

55. Dai X, Lu L, Deng S, Meng J, Wan C, Huang J. et al. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer. Theranostics. 2020;10:9332-47

56. Yu FX, Zhao B, Guan KL. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015;163:811-28

57. Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nature reviews Molecular cell biology. 2019;20:211-26

58. Zhang Z, Du J, Wang S, Shao L, Jin K, Li F. et al. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. Mol Cell. 2019;73:7-21.e7

59. Crawford JJ, Bronner SM, Zbieg JR. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review. Expert opinion on therapeutic patents. 2018;28:867-73

60. Koo JH, Guan KL. Interplay between YAP/TAZ and Metabolism. Cell metabolism. 2018;28:196-206

61. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147:759-72

62. Mazzolini R, Gonzàlez N, Garcia-Garijo A, Millanes-Romero A, Peiró S, Smith S. et al. Snail1 transcription factor controls telomere transcription and integrity. Nucleic acids research. 2018;46:146-58

63. Viñas-Castells R, Beltran M, Valls G, Gómez I, García JM, Montserrat-Sentís B. et al. The hypoxia-controlled FBXL14 ubiquitin ligase targets SNAIL1 for proteasome degradation. The Journal of biological chemistry. 2010;285:3794-805

64. Wu Y, Wang Y, Lin Y, Liu Y, Wang Y, Jia J. et al. Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun. 2017;8:14228

65. Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:11

66. Liu J, Ma J, Liu Y, Xia J, Li Y, Wang ZP. et al. PROTACs: A novel strategy for cancer therapy. Semin Cancer Biol. 2020;67:171-9

67. An S, Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018;36:553-62

68. Sonego M, Pellarin I, Costa A, Vinciguerra GLR, Coan M, Kraut A. et al. USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability. Science advances. 2019;5:eaav3235

69. Ma A, Tang M, Zhang L, Wang B, Yang Z, Liu Y. et al. USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis. Oncogene. 2019;38:2405-19

70. Mussell A, Shen H, Chen Y, Mastri M, Eng KH, Bshara W. et al. USP1 Regulates TAZ Protein Stability Through Ubiquitin Modifications in Breast Cancer. Cancers (Basel). 2020 12

71. Liao Y, Shao Z, Liu Y, Xia X, Deng Y, Yu C. et al. USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2021;40:201

72. Zhao Y, Wang X, Wang Q, Deng Y, Li K, Zhang M. et al. USP2a Supports Metastasis by Tuning TGF-β Signaling. Cell Rep. 2018;22:2442-54

73. Xiong B, Huang J, Liu Y, Zou M, Zhao Z, Gong J. et al. Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A. Cellular oncology (Dordrecht). 2021;44:329-43

74. Wu X, Liu M, Zhu H, Wang J, Dai W, Li J. et al. Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer. J Exp Clin Cancer Res. 2019;38:277

75. Li F, Hu Q, He T, Xu J, Yi Y, Xie S. et al. The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness. Cancers (Basel). 2020 12

76. Geng N, Li Y, Zhang W, Wang F, Wang X, Jin Z. et al. A PAK5-DNPEP-USP4 axis dictates breast cancer growth and metastasis. Int J Cancer. 2020;146:1139-51

77. Meng J, Ai X, Lei Y, Zhong W, Qian B, Qiao K. et al. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma. Theranostics. 2019;9:573-87

78. Xue S, Wu W, Wang Z, Lu G, Sun J, Jin X. et al. USP5 Promotes Metastasis in Non-Small Cell Lung Cancer by Inducing Epithelial-Mesenchymal Transition via Wnt/β-Catenin Pathway. Frontiers in pharmacology. 2020;11:668

79. Zeng H, Yuan F, Mi Y, Xian G, Qin C, Zhang D. As an independent prognostic factor, USP6 promotes the invasion and metastasis of colon cancer. Biochem Biophys Res Commun. 2018;505:816-22

80. Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D. et al. Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs. Cancer Res. 2018;78:5349-62

81. Wu HT, Kuo YC, Hung JJ, Huang CH, Chen WY, Chou TY. et al. K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression. Nat Commun. 2016;7:13644

82. Ma M, Yu N. Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis. Onco Targets Ther. 2016;9:1559-69

83. Yang X, Jin J, Yang J, Zhou L, Mi S, Qi G. Expression of Ubiquitin-specific protease 7 in oral squamous cell carcinoma promotes tumor cell proliferation and invasion. Genetics and molecular biology. 2021;44:e20210058

84. Ye M, He J, Zhang J, Liu B, Liu X, Xie L. et al. USP7 promotes hepatoblastoma progression through activation of PI3K/AKT signaling pathway. Cancer biomarkers: section A of Disease markers. 2021;31:107-17

85. Xiang M, Liang L, Kuang X, Xie Z, Liu J, Zhao S. et al. Pharmacological inhibition of USP7 suppresses growth and metastasis of melanoma cells in vitro and in vivo. J Cell Mol Med. 2021;25:9228-40

86. Jing X, Chen Y, Chen Y, Shi G, Lv S, Cheng N. et al. Down-regulation of USP8 Inhibits Cholangiocarcinoma Cell Proliferation and Invasion. Cancer management and research. 2020;12:2185-94

87. Qiu H, Kong J, Cheng Y, Li G. The expression of ubiquitin-specific peptidase 8 and its prognostic role in patients with breast cancer. J Cell Biochem. 2018;119:10051-8

88. Liu L, Yao D, Zhang P, Ding W, Zhang X, Zhang C. et al. Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer. Oncology reports. 2017;38:3531-7

89. Wu Y, Yu X, Yi X, Wu K, Dwabe S, Atefi M. et al. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res. 2017;77:1383-94

90. Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye S. et al. Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein. Mol Oncol. 2020;14:197-210

91. Li B, Qi ZP, He DL, Chen ZH, Liu JY, Wong MW. et al. NLRP7 deubiquitination by USP10 promotes tumor progression and tumor-associated macrophage polarization in colorectal cancer. J Exp Clin Cancer Res. 2021;40:126

92. Sun H, Ou B, Zhao S, Liu X, Song L, Liu X. et al. USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway. EBioMedicine. 2019;48:236-47

93. Zhang C, Xie C, Wang X, Huang Y, Gao S, Lu J. et al. Aberrant USP11 expression regulates NF90 to promote proliferation and metastasis in hepatocellular carcinoma. American journal of cancer research. 2020;10:1416-28

94. Garcia DA, Baek C, Estrada MV, Tysl T, Bennett EJ, Yang J. et al. USP11 Enhances TGFβ-Induced Epithelial-Mesenchymal Plasticity and Human Breast Cancer Metastasis. Mol Cancer Res. 2018;16:1172-84

95. Zhang S, Xie C, Li H, Zhang K, Li J, Wang X. et al. Ubiquitin-specific protease 11 serves as a marker of poor prognosis and promotes metastasis in hepatocellular carcinoma. Laboratory investigation; a journal of technical methods and pathology. 2018;98:883-94

96. Luo Q, Wu X, Nan Y, Chang W, Zhao P, Zhang Y. et al. TRIM32/USP11 Balances ARID1A Stability and the Oncogenic/Tumor-Suppressive Status of Squamous Cell Carcinoma. Cell Rep. 2020;30:98-111.e5

97. Park MK, Yao Y, Xia W, Setijono SR, Kim JH, Vila IK. et al. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nat Commun. 2019;10:636

98. Sheng B, Wei Z, Wu X, Li Y, Liu Z. USP12 promotes breast cancer angiogenesis by maintaining midkine stability. Cell Death Dis. 2021;12:1074

99. Zhang Y, Jia J, Jin W, Cao J, Fu T, Ma D. et al. Lidocaine inhibits the proliferation and invasion of hepatocellular carcinoma by downregulating USP14 induced PI3K/Akt pathway. Pathology, research and practice. 2020;216:152963

100. Hang C, Gong C, Fang Y, Chen L, Zhu J. Ubiquitin-specific protease 14 (USP14) promotes proliferation and metastasis in pancreatic ductal adenocarcinoma. Journal of molecular histology. 2021;52:187-96

101. Yao XQ, Li L, Piao LZ, Zhang GJ, Huang XZ, Wang Y. et al. Overexpression of Ubiquitin-Specific Protease15 (USP15) Promotes Tumor Growth and Inhibits Apoptosis and Correlated With Poor Disease-Free Survival in Hepatocellular Carcinoma. Technology in cancer research & treatment. 2020;19:1533033820967455

102. Zhong M, Zhou L, Fang Z, Yao YY, Zou JP, Xiong JP. et al. Ubiquitin-specific protease 15 contributes to gastric cancer progression by regulating the Wnt/β-catenin signaling pathway. World journal of gastroenterology. 2021;27:4221-35

103. Song C, Peng J, Wei Y, Shao J, Chen X, Zhang X. et al. USP18 promotes tumor metastasis in esophageal squamous cell carcinomas via deubiquitinating ZEB1. Exp Cell Res. 2021;409:112884

104. Wu C, Luo K, Zhao F, Yin P, Song Y, Deng M. et al. USP20 positively regulates tumorigenesis and chemoresistance through β-catenin stabilization. Cell Death Differ. 2018;25:1855-69

105. Chen Y, Zhou B, Chen D. USP21 promotes cell proliferation and metastasis through suppressing EZH2 ubiquitination in bladder carcinoma. Onco Targets Ther. 2017;10:681-9

106. Yun SI, Hong HK, Yeo SY, Kim SH, Cho YB, Kim KK. Ubiquitin-Specific Protease 21 Promotes Colorectal Cancer Metastasis by Acting as a Fra-1 Deubiquitinase. Cancers (Basel). 2020 12

107. Ma Y, Fu HL, Wang Z, Huang H, Ni J, Song J. et al. USP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression by stabilizing BMI1 protein. Oncotarget. 2017;8:33329-42

108. Li Y, Yang Y, Li J, Liu H, Chen F, Li B. et al. USP22 drives colorectal cancer invasion and metastasis via epithelial-mesenchymal transition by activating AP4. Oncotarget. 2017;8:32683-95

109. Zhang K, Yang L, Wang J, Sun T, Guo Y, Nelson R. et al. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell communication and signaling: CCS. 2019;17:167

110. Liu H, Liu N, Zhao Y, Zhu X, Wang C, Liu Q. et al. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling. Aging. 2019;11:9643-60

111. Li J, Yuan S, Norgard RJ, Yan F, Yamazoe T, Blanco A. et al. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer. Cancer Immunol Res. 2020;8:282-91

112. Kosinsky RL, Zerche M, Saul D, Wang X, Wohn L, Wegwitz F. et al. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity. Cell Death Differ. 2020;27:1328-40

113. Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F. et al. miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25. Molecular cancer. 2014;13:166

114. Li L, Zhou H, Zhu R, Liu Z. USP26 promotes esophageal squamous cell carcinoma metastasis through stabilizing Snail. Cancer Lett. 2019;448:52-60

115. Zhao LJ, Zhang T, Feng XJ, Chang J, Suo FZ, Ma JL. et al. USP28 contributes to the proliferation and metastasis of gastric cancer. J Cell Biochem. 2018

116. Flügel D, Görlach A, Kietzmann T. GSK-3β regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1α. Blood. 2012;119:1292-301

117. Qian W, Li Q, Wu X, Li W, Li Q, Zhang J. et al. Deubiquitinase USP29 promotes gastric cancer cell migration by cooperating with phosphatase SCP1 to stabilize Snail protein. Oncogene. 2020;39:6802-15

118. Gan Q, Shao J, Cao Y, Lei J, Xie P, Ge J. et al. USP33 regulates c-Met expression by deubiquitinating SP1 to facilitate metastasis in hepatocellular carcinoma. Life Sci. 2020;261:118316

119. Buus R, Faronato M, Hammond DE, Urbe S, Clague MJ. Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells. Curr Biol. 2009;19:1463-6

120. Huang Z, Wen P, Kong R, Cheng H, Zhang B, Quan C. et al. USP33 mediates Slit-Robo signaling in inhibiting colorectal cancer cell migration. Int J Cancer. 2015;136:1792-802

121. Xia Y, Wang L, Xu Z, Kong R, Wang F, Yin K. et al. Reduced USP33 expression in gastric cancer decreases inhibitory effects of Slit2-Robo1 signalling on cell migration and EMT. Cell Prolif. 2019;52:e12606

122. Cai J, Li M, Wang X, Li L, Li Q, Hou Z. et al. USP37 Promotes Lung Cancer Cell Migration by Stabilizing Snail Protein via Deubiquitination. Front Genet. 2019;10:1324

123. Qin T, Li B, Feng X, Fan S, Liu L, Liu D. et al. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity. Journal of Experimental & Clinical Cancer Research. 2018 37

124. Xiao Z, Chang L, Kim J, Zhang P, Hang Q, Yap S. et al. USP37 is a SNAI1 deubiquitinase. American journal of cancer research. 2019;9:2749-59

125. Liu T, Sun B, Zhao X, Li Y, Zhao X, Liu Y. et al. USP44+ Cancer Stem Cell Subclones Contribute to Breast Cancer Aggressiveness by Promoting Vasculogenic Mimicry. Mol Cancer Ther. 2015;14:2121-31

126. Park JM, Lee JE, Park CM, Kim JH. USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization. Molecules and cells. 2019;42:17-27

127. Tian M, Zhu R, Ding F, Liu Z. Ubiquitin-specific peptidase 46 promotes tumor metastasis through stabilizing ENO1 in human esophageal squamous cell carcinoma. Exp Cell Res. 2020;395:112188

128. Silvestrini VC, Thome CH, Albuquerque D, de Souza Palma C, Ferreira GA, Lanfredi GP. et al. Proteomics analysis reveals the role of ubiquitin specific protease (USP47) in Epithelial to Mesenchymal Transition (EMT) induced by TGFbeta2 in breast cells. J Proteomics. 2020;219:103734

129. Choi BJ, Park SA, Lee SY, Cha YN, Surh YJ. Hypoxia induces epithelial-mesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 47-mediated stabilization of Snail: A potential role of Sox9. Sci Rep. 2017;7:15918

130. Yu L, Dong L, Wang Y, Liu L, Long H, Li H. et al. Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression. Cancer Lett. 2019;448:40-51

131. Lei X, Li X, Chen H, Liu Z. USP48 Sustains Chemoresistance and Metastasis in Ovarian Cancer. Current cancer drug targets. 2020;20:689-99

132. Zhang Z, Li J, Ou Y, Yang G, Deng K, Wang Q. et al. CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism. Signal Transduct Target Ther. 2020;5:25

133. Zhou Z, Zhang P, Hu X, Kim J, Yao F, Xiao Z. et al. USP51 promotes deubiquitination and stabilization of ZEB1. American journal of cancer research. 2017;7:2020-31

134. Che X, Jian F, Jia N, Zheng Y, Jiang Y, Feng W. FAT4-USP51 complex regulates the proliferation and invasion of endometrial cancer via Hippo pathway. American journal of translational research. 2019;11:2784-800

135. Fraile JM, Campos-Iglesias D, Rodríguez F, Español Y, Freije JM. The deubiquitinase USP54 is overexpressed in colorectal cancer stem cells and promotes intestinal tumorigenesis. Oncotarget. 2016;7:74427-34

136. Zhou H, Liu Y, Zhu R, Ding F, Cao X, Lin D. et al. OTUB1 promotes esophageal squamous cell carcinoma metastasis through modulating Snail stability. Oncogene. 2018;37:3356-68

137. Zhou Y, Wu J, Fu X, Du W, Zhou L, Meng X. et al. OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer. Molecular Cancer. 2014;13:258

138. Li J, Cheng D, Zhu M, Yu H, Pan Z, Liu L. et al. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer. Theranostics. 2019;9:179-95

139. Zhang Z, Du J, Wang S, Shao L, Jin K, Li F. et al. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. Mol Cell. 2019;73:7-21 e7

140. Zhang P, Li C, Li H, Yuan L, Dai H, Peng Z. et al. Ubiquitin ligase CHIP regulates OTUD3 stability and suppresses tumour metastasis in lung cancer. Cell Death Differ. 2020;27:3177-95

141. Yuan L, Lv Y, Li H, Gao H, Song S, Zhang Y. et al. Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat Cell Biol. 2015;17:1169-81

142. Liu X, Zhang X, Peng Z, Li C, Wang Z, Wang C. et al. Deubiquitylase OTUD6B Governs pVHL Stability in an Enzyme-Independent Manner and Suppresses Hepatocellular Carcinoma Metastasis. Adv Sci (Weinh). 2020;7:1902040

143. Lin DD, Shen Y, Qiao S, Liu WW, Zheng L, Wang YN. et al. Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma. Front Oncol. 2019;9:862

144. Qin J, Zhou Z, Chen W, Wang C, Zhang H, Ge G. et al. BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. Nat Commun. 2015;6:8471

145. Amato E, Mafficini A, Hirabayashi K, Lawlor RT, Fassan M, Vicentini C. et al. Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. J Pathol. 2019;247:123-34

146. Gupta MP, Lane AM, DeAngelis MM, Mayne K, Crabtree M, Gragoudas ES. et al. Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. JAMA Ophthalmol. 2015;133:881-7

147. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (New York, NY). 2010;330:1410-3

148. de Jel MM, Schott M, Lamm S, Neuhuber W, Kuphal S, Bosserhoff AK. Loss of CYLD accelerates melanoma development and progression in the Tg(Grm1) melanoma mouse model. Oncogenesis. 2019;8:56

149. Miliani de Marval P, Lutfeali S, Jin JY, Leshin B, Selim MA, Zhang JY. CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels. Cancer prevention research (Philadelphia, Pa). 2011;4:851-9

150. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, Spruss T. et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med. 2009;206:221-32

151. Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K. et al. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun. 2015;6:6153

152. Jang MJ, Baek SH, Kim JH. UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction. Cancer Lett. 2011;302:128-35

153. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim HJ. et al. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene. 2009;28:117-27

154. Wang W, Zou L, Zhou D, Zhou Z, Tang F, Xu Z. et al. Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway. Mol Carcinog. 2016;55:1329-42

155. Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S. et al. Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res. 2007;13:27-37

156. Liu S, González-Prieto R, Zhang M, Geurink PP, Kooij R, Iyengar PV. et al. Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFβ-Induced Breast Cancer Metastasis. Clin Cancer Res. 2020;26:1460-73

157. Liu D, Song Z, Wang X, Ouyang L. Ubiquitin C-Terminal Hydrolase L5 (UCHL5) Accelerates the Growth of Endometrial Cancer via Activating the Wnt/β-Catenin Signaling Pathway. Front Oncol. 2020;10:865

158. Huang M, Xiong H, Luo D, Xu B, Liu H. CSN5 upregulates glycolysis to promote hepatocellular carcinoma metastasis via stabilizing the HK2 protein. Exp Cell Res. 2020;388:111876

159. Zhang S, Hong Z, Chai Y, Liu Z, Du Y, Li Q. et al. CSN5 promotes renal cell carcinoma metastasis and EMT by inhibiting ZEB1 degradation. Biochem Biophys Res Commun. 2017;488:101-8

160. Hou J, Deng Q, Zhou J, Zou J, Zhang Y, Tan P. et al. CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR. Oncogene. 2017;36:1134-44

161. Mao Z, Sang MM, Chen C, Zhu WT, Gong YS, Pei DS. CSN6 Promotes the Migration and Invasion of Cervical Cancer Cells by Inhibiting Autophagic Degradation of Cathepsin L. Int J Biol Sci. 2019;15:1310-24

162. Zou H, Chen H, Zhou Z, Wan Y, Liu Z. ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4. Cancer Lett. 2019;467:19-28

Author contact

Corresponding authors: Feng Gao, E-mail: gf0731edu.cn. Pengfei Rong, E-mail: rongpengfei66com. Wei Wang, E-mail: cjr.wangwei163.com. Wei Li, E-mail: weililxedu.cn. Tel: +86-0731-88618643

Received 2021-11-24
Accepted 2022-2-19
Published 2022-3-6

Citation styles

©2024 Ivyspring International Publisher. Terms of use